Clinical trial NCT00492830: Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
Official title: A Phase 1, Open-label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Neoplasm Metastasis
Keywords: Phase 1
TRC093
denatured collagen
solid tumor
antibody
TRACON
Locally advanced solid tumors
Metastatic solid tumors
Lead sponsor: Tracon Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2007-06-27
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.

Detailed description: In addition to safety, this study will also evaluate pharmacokinetics, tumor response, and anti-TRC093 antibody formation.

Eligibility criteria: Inclusion Criteria:

A patient will be eligible for study participation only if all of the following criteria apply:

1. The patient has given informed consent.
2. The patient is willing and able to abide by the protocol.
3. The patient is at least 18 years old.
4. The patient has advanced cancer and is not eligible for treatment or no effective treatment exists.
5. Significant toxicities resulting from prior therapy must have recovered.
6. If the patient is a female of childbearing potential, she is using an acceptable/effective method of contraception.
7. If the patient is a female, she has had a negative serum pregnancy test within the past 30 days.
8. The patient has adequate ability to perform activities of daily living.
9. The patient has adequate organ function as assessed by laboratory tests

Exclusion Criteria:

A patient will not be eligible for study participation if any of the following criteria apply:

1. The patient weighs more than 264 lbs.
2. The patient has had a major surgical procedure, or significant injury within the past 28 days or there is an anticipation of the need for major surgery during the course of the study.
3. The patient has received treatment for their cancer, including radiation (minimal amount of localized radiation may be allowed), within the past 28 days.
4. The patient has known brain tumors.
5. The patient experienced blood clots within six months prior to study start.
6. The patient has a non-healing wound, ulcer or bone fracture.
7. The patient received recent thrombolytic or anticoagulant therapy.
8. The patient has an unstable medical condition or significant comorbid pathophysiology (e.g. active infection, poorly controlled diabetes, unstable angina, severe heart failure) that would interfere with his/her participation in the study.
9. The patient enrolled, or plans to enroll, in a concurrent treatment protocol with another investigational product.
10. The patient is receiving, or plans to receive, an anti-cancer therapy during the study with the exception of patients receiving chronic luteinizing hormone-releasing hormone (LHRH) agonists.

Primary outcomes:
measure: Safety and tolerability will be evaluated
timeFrame: Through last patient last visit
measure: Dose Limiting Toxicities
timeFrame: 28 day evaluation period
Secondary outcomes:
measure: Pharmacokinetics of TRC093 monoclonal antibody
timeFrame: Through last patient last visit
measure: Number of responses by tumor type
timeFrame: Through last patient last visit
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Phoenix
country: United States
state: Arizona
city: Santa Monica
country: United States
state: California
Study officials:
References: